




|  | Moderate COVID-19 | Severe COVID-19  | Relative Risk (95% CI); [*; p-value] | Total             |
|--|-------------------|------------------|--------------------------------------|-------------------|
| Number   | 70.8% (80 / 113)  | 29.2% (33 / 113) |                                      | 113               |
| Age (years)  | 62.66 ± 16.1      | 63.67 ± 19.3     | [n.s.]                               | 62.96 ± 17.0      |
| Sex  |                   |                  |                                      |                   |
| Male   | 45% (36 / 80)     | 48.48% (16 / 33) | 1.07 (.70 - 1.65)                    | 46.02% (52 / 113) |
| Female   | 55% (44 / 80)     | 51.52% (17 / 33) | .94 (.64 - 1.38)                     | 53.98% (61 / 113) |
| Ethnicity  |                   |                  |                                      |                   |
| American Indian / Alaskan Native   | 0% (0 / 80)       | 0% (0 / 33)      | --                                   | 0% (0 / 113)      |
| Asian  | 1.25% (1 / 80)    | 0% (0 / 33)      | --                                   | 0.88% (1 / 113)   |
| Black / African American   | 27.5% (22 / 80)   | 33.33% (11 / 33) | 1.21 (.67 - 2.21)                    | 29.2% (33 / 113)  |
| Native Hawaiian / Pacific Islander                                       | 0% (0 / 80)       | 0% (0 / 33)      | -                                    | 0% (0 / 113)      |
| White  | 53.75% (43 / 80)  | 54.55% (18 / 33) | 1.01 (.70 - 1.47)                    | 53.98% (61 / 113) |
| Hispanic   | 12.5% (10 / 80)   | 12.12% (4 / 33)  | .97 (.33 - 2.87)                     | 12.39% (14 / 113) |
| Multiple   | 0% (0 / 80)       | 0% (0 / 33)      | --                                   | 0% (0 / 113)      |
| Unknown  | 5% (4 / 80)       | 0% (0 / 33)      | n.c.                                 | 3.54% (4 / 113)   |
| BMI  |                   |                  |                                      |                   |
| <18.5  | 0% (0 / 80)       | 6.06% (2 / 33)   | n.c.                                 | 1.77% (2 / 113)   |
| 18.5-24.9  | 21.25% (17 / 80)  | 9.09% (3 / 33)   | .43 (.13 - 1.36)                     | 17.7% (20 / 113)  |
| 25.0-29.9  | 32.5% (26 / 80)   | 24.24% (8 / 33)  | .75 (.38 - 1.47)                     | 30.09% (34 / 113) |
| 30-35  | 27.5% (22 / 80)   | 30.3% (10 / 33)  | 1.10 (.59 - 2.06)                    | 28.32% (32 / 113) |
| >35  | 18.75% (15 / 80)  | 30.3% (10 / 33)  | 1.62 (.81 - 3.22)                    | 22.12% (25 / 113) |
| COVID Risk Factors   |                   |                  |                                      |                   |
| None   | 27.5% (22 / 80)   | 30.3% (10 / 33)  | 1.10 (.59 - 2.06)                    | 28.32% (32 / 113) |
| Cancer Treatment within 1 year   | 7.5% (6 / 80)     | 15.15% (5 / 33)  | 2.02 (.66 - 6.16)                    | 9.73% (11 / 113)  |
| Chronic Heart Disease  | 27.5% (22 / 80)   | 24.24% (8 / 33)  | .88 (.44 - 1.78)                     | 26.55% (30 / 113) |
| Hypertension   | 53.75% (43 / 80)  | 48.48% (16 / 33) | .90 (.60 - 1.35)                     | 52.21% (59 / 113) |
| Chronic Lung Disease (asthma, COPD, ILD)                                 | 26.25% (21 / 80)  | 18.18% (6 / 33)  | .69 (.31 - 1.56)                     | 23.89% (27 / 113) |
| Immunosuppression  | 11.25% (10 / 80)  | 6.06% (2 / 33)   | .52 (.12 - 2.29)                     | 9.73% (12 / 113)  |
| Solid Organ Transplant   | 6.25% (4 / 80)    | 3.03% (1 / 33)   | .60 (.07 - 5.16)                     | 4.42% (5 / 113)   |
| HIV* (with anti-viral treatment; CD4 > 400)                              | 2.5% (2 / 80)     | 0% (0 / 33)      | n.c.                                 | 1.77% (2 / 113)   |
| Other (Multiple Sclerosis, Rheumatoid Arthritis, Scleroderma, Cirrhosis) | 3.75% (3 / 80)    | 3.03% (1 / 33)   | 1.21 (.11 - 12.91)                   | 3.54% (4 / 113)   |
| Presenting Symptoms  |                   |                  |                                      |                   |
| Headache   | 56.9% (33 / 58)   | 47.37% (9 / 19)  | .83 (.49 - 1.41)                     | 54.55% (42 / 77)  |
| Objective Fever (> 100.3 °F / 37.9 °C)                                   | 64.29% (36 / 56)  | 65% (13 / 20)    | 1.01 (.69 - 1.47)                    | 64.47% (49 / 76)  |
| Cough  | 77.19% (44 / 57)  | 65% (13 / 20)    | .84 (.59 - 1.20)                     | 74.03% (57 / 77)  |
| Dyspnea  | 64.41% (38 / 59)  | 75% (15 / 20)    | 1.16 (.85 - 1.60)                    | 67.09% (53 / 79)  |
| Rhinorrhea   | 30.36% (17 / 56)  | 35.29% (6 / 17)  | 1.16 (.55 - 2.48)                    | 31.51% (23 / 73)  |
| Sore Throat  | 27.59% (16 / 58)  | 22.22% (4 / 18)  | .81 (.31 - 2.10)                     | 26.32% (20 / 76)  |
| Nausea   | 48.28% (28 / 58)  | 41.18% (7 / 17)  | .85 (.46 - 1.60)                     | 46.67% (35 / 75)  |
| Vomiting   | 31.03% (18 / 58)  | 27.78% (5 / 18)  | .90 (.39 - 2.07)                     | 30.26% (23 / 76)  |
| Diarrhea   | 50% (29 / 58)     | 35.29% (6 / 17)  | .71 (.35 - 1.41)                     | 44% (33 / 75)     |
| Abdominal Pain   | 31.03% (18 / 58)  | 5.88% (1 / 17)   | .19 (.03 - 1.32)                     | 25.33% (19 / 75)  |
| Hypogeusia   | 37.04% (20 / 54)  | 33.33% (5 / 15)  | .90 (.41 - 1.99)                     | 36.23% (25 / 69)  |
| Anosmia  | 31.37% (16 / 51)  | 33.33% (5 / 15)  | 1.06 (.47 - 2.42)                    | 31.82% (21 / 66)  |
| All Cause Mortality  | 3.75% (3 / 80)    | 27.27% (9 / 33)  | 7.27 (2.10 - 25.19)***; [p = .0002]  | 10.62% (12 / 113) |

**Table 1:** Basic Demographics for COVID-19 Cohort. Unless otherwise noted, relative risks were not statistically significant. Moderate (Clinical Score 1-3) and severe (Clinical Score 4-5) disease status were assigned as described in Methods. Percentages of sub-group (moderate or severe) are shown for each category with respective counts in parenthesis. Average age was calculated with accompanying sample standard deviation. Ethnicity and BMI were extracted from most recent electronic medical record (EMR) data. Select COVID-19 Risk Factors were scored by a clinical infectious disease physician. Presenting symptoms were recorded primarily through direct interview with patient or surrogate.

"--": No data available; [n.s.]: Not statistically significant; "n.c": Not calculable; "\*\*\*": Chi-Square  $\chi^2$  (1, N = 113) = 13.62, p = .0002

# Extended data Fig1: Age and BMI cohort distributions and Select Medications distribution



**D**

Changes in IL-6, according to tocilizumab, after controlling, age, ICU admission and days from symptom onset, accounting for multiple observations per person (GEE).


| Covariate               | Coefficient | 95% CI            |
|-------------------------|-------------|-------------------|
| <b>Tocilizumab</b>      | <b>0.55</b> | <b>0.07, 1.04</b> |
| ICU admission           | 0.48        | -0.02, 0.99       |
| Days from symptom onset | -0.02       | -0.04, -0.003     |
| Age                     | 0.01        | 0.0003, 0.02      |

This analysis excludes two individuals whose IL-6 was measured before receiving tocilizumab.

Changes in T cell count, according to age, ICU admission and days from symptom onset, accounting for multiple observations per person (GEE).


| Covariate               | Coefficient  | 95% CI             |
|-------------------------|--------------|--------------------|
| ICU admission           | -13.43       | -19.32, -7.55      |
| Days from symptom onset | -0.15        | -0.41, 0.11        |
| <b>Age</b>              | <b>-0.16</b> | <b>-0.33, 0.02</b> |

# Extended Data Fig. 2: Overview of cellular immune changes in COVID-19 patients




**Extended Data Fig3: Overview of cytokine and chemokine profiles of COVID-19 patients**

**A**




### Extended Data Fig3: Overview of cytokine and chemokine profiles of COVID-19 patients















# Extendend Data Fig 4: Longitudinal cytokine and chemokine profiles in COVID-19 patients

— Severe  
— Moderate


A






# Extended Data Fig.5: T cell immune profile in moderate vs. severe patients

A




B






# Extended Fig 6: Early cytokine profile distinguishes moderate and severe outcomes



**Extended Data Fig 7: Distribution of days from symptom onset stratified by collection time point**



# Extended Data Fig 8: Risk of death according to biomarkers levels

Risk of death:

